A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.:
Source: Neurology Read More
Pretreatment Meningoccal Vaccination Rates High Among Patients With NMOSD Transitioning From Rituximab to Ravulizumab
Related Posts
<![CDATA[How Early Environmental Detection Could
Refine Parkinson Disease Risk Models: Rodolfo Savica, MD,
PhD]]>
<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>
